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1. Introduction 
Glaucoma is a heterogeneous group of optic neuropathies which can lead to optic nerve loss 
of optic nerve fibers and permanent loss of vision. It is the second most prevalent cause of 
bilateral blindness in the Western World and it affects several million people worldwide. 
(Ray et al., 2003). There are different types of glaucoma: adult-onset open-angle glaucoma, 
the commonest form of the disease, representing almost half of all cases; as juvenile-onset 
open-angle glaucoma, followed by juvenile-onset open-angle glaucoma (Weisschuh and 
Schiefer, 2003), and as congenital glaucoma (CG), a clinical and genetic entity distinct from 
the juvenile form. 
CG may be associated with ocular malformation, such as aniridia (Lee et al., 2003) or 
congenital hydrocephalus and anterior segment dysgenesis (Mandal et al., 2002). It results 
from poorly understood developmental abnormalities of the ocular drainage structures and 
is clinically characterized by high intraocular pressure (IOP), epiphora, corneal oedema, 
photophobia, blepharospasm and ocular enlargement (Libby et al., 2003). The disease is 
bilateral in approximately 75% of cases. CG incidence varies substantially among countries: 
it is estimated to occur in 1/10,000 births in Europe, in 1/2500 in Saudi Arabia and 1/1250 in 
the gypsy population of Slovakia. (Online Mendelian Inheritance in Man, OMIM 231300).  
An increase in IOP, untreated either with surgery or pharmacological therapy, results in 
ocular enlargement (buphthalmos) and rapidly progressive cupping of the optic nerve with 
severe and irreversible alteration of the visual field (Belmouden et al., 2002, Bruttini et al., 
2003). Early recognition and therapy can significantly improve the child's visual function. 
Onset of an aggressive form of glaucoma occurs between birth and 3 years of age. The 
disease has higher prevalence in males (2:1 M/F). 
Most cases of CG are sporadic and recessive inheritance of CG is common, with almost 
complete penetrance in populations with a high consanguinity rate. Reduced penetrance 
(40% in some populations) and various phenotypic forms suggests a polygenic inheritance 
pattern or multifactorial aetiologies. 
Genetic linkage studies, started in 1995, identified two separate loci (GLC3A on 2p21 and 
GLC3B on 1p36) associated with the disease, thus confirming that CG is genetically 
heterogeneous (Ohtake et al., 2003) (Sarfarazi et al., 1995). A few years later Sarfarazi 
reported that the cytochrome P4501B1 gene (CYP1B1, OMIM 601771), located within the 
GLC3A locus, was mutated in individuals with CG (Akarsu et al., 1996). 
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CYP1B1 belongs to a multigene superfamily of monomeric mixed-function 
monooxygenases, responsible for the phase I metabolism of a wide range of structurally 
different substrates including steroids and retinoids (Stoilov et al., 1996, Hayes et al., 1997). 
A specific CYP1B1 metabolite is most probably required for normal eye development, and 
its deficiency (or toxic accumulation) may result in CG (Zhang et al., 2000). 
The CYP1B1 gene maps to 2p22-p21, contains 3 exons and 2 introns, and is expressed in 
several normal human tissues (Stoilov et al., 2001). Northern hybridization analysis showed 
strong expression of CYP1B1 in the anterior uveal tract, which is involved in secretion of the 
aqueous humor and in the regulation of outflow facility, processes that could contribute to 
the elevated intraocular pressure characteristic of CG (Sutter et al., 1994).  
An extensive allelic heterogeneity was illustrated by a comprehensive sequence analysis of 
the translated regions of the CYP1B1 gene in 22 CG families and in 100 randomly selected 
normal individuals. Sixteen mutations and 6 polymorphisms were identified. The positions 
affected by these changes were evaluated by building a 3-dimensional homology model of 
the conserved C-terminal half of CYP1B1. These mutations may interfere with the heme 
incorporation by affecting the hinge region and/or the conserved core structures (CCS) that 
determine the proper folding and heme-binding ability of P450 molecules. In contrast, all 
polymorphic sites were poorly conserved and located outside the CCS (Stoilov et al., 1998).  
More than 50 CYP1B1 pathogenic mutations, including 34 missense/nonsense substitutions, 
10 small deletions, 6 small insertions, a 27 bp duplication and a deletion involving part of 
intron 2 and exon 3, have been described in various ethnic groups (Human Gene Mutations 
Database). Two CYP1B1 mutations, Met1Thr and Trp57Stop, in a compound heterozygosis 
status, have been identified as the molecular basis of Peters’ anomaly that consists of corneal 
opacity, defects in the posterior structures of the cornea, iridocorneal and/or 
keratolenticular adhesions (Stoilov et al., 1998). 
Mutations in CYP1B1 were found also in patients with juvenile glaucoma (JOAG),  an early-
onset form of open angle glaucoma that can be caused by a mutation in the gene encoding 
myocilin (MYOC/TIGR). 
Vincent et al. studied the role of the CYP1B1 and MYOC/TIGR and found that 
MYOC/TIGR mutations included cases of juvenile glaucoma (either with or without 
pigmentary glaucoma) and mixed-mechanism glaucoma, and CYP1B1 mutations involved 
cases of juvenile open-angle glaucoma as well as cases of congenital glaucoma. That paper 
emphasized the genetic heterogeneity of juvenile and congenital glaucoma and 
demonstrated that the spectrum of expression of MYOC/ TIGR and CYP1B1 mutations is 
greater than expected. It also appeared that CYP1B1 may act as a modifier of MYOC/ TIGR 
expression and that these 2 genes may interact through a common pathway (Vincent et al., 
2001). Both CYP1B1 and the MYOC/TIGR genes are expressed in the iris, trabecular 
meshwork, and ciliary body of the eye (Vincent et al., 2002).  
Different CYP1B1 mutations together with a common MYOC/TIGR mutation (Gln48His) 
have been reported in CG patients (Ming and Muenke, 2002, Chakrabarti et al., 2005), thus 
suggesting a role for the MYOC gene in congenital glaucoma via digenic interactions with 
CYP1B1. 
In 22 Saudi Arabian families, 40 apparently unaffected individuals had mutations in 
CYP1B1 and haplotypes identical to their affected siblings. Analysis of these relatives 
suggested the presence of a dominant modifier locus that is not linked genetically to 
CYP1B1. Linkage and Southern analyses excluded 3 candidate modifier loci, the 
arylhydrocarbon receptor (AHR) on 7p15, the arylhydrocarbon receptor nuclear translocator 
www.intechopen.com
 
Molecular Analysis of Italian Patients with Congenital Glaucoma 
 
73 
(ARNT) on 1q21, and the CYP2D6 gene on 22q13.1 (Kaur et al., 2005, Bejjani et al., 2000, 
Libby et al., 2003). 
To determine the possible role of the genetic defects described in CG cases in Italy, 
molecular analysis was undertaken, and the CYP1B1 and MYOC genes were screened for 
mutations. We describe here the pathogenic mutations found, some of which are not 
published, and the haplotype for five intragenic SNPs (Single Nucleotide Polymorphisms) 
associated with the mutations identified. 
2. Methods 
2.1 Subjects 
Peripheral blood samples were collected from 72 patients (10 subjects belonging to 5 families 
and 62 unrelated subjects) with a diagnosis of  bilateral CG coming from different Italian 
regions. A clinical report with demographic data and clinical evaluation was obtained for 
every patient. Reports contain subjective symptoms (irritability, sensitivity to light, tearing 
of the eyes) and objective evaluation (corneal diameter enlargement, type of corneal 
oedema, rupture of Descemet membrane, increase of IOP). Age of disease onset and number 
of surgical procedures are described in Table I. 
 
ID 
Age at 
Diagnosis 
(mo) 
N° of 
Surgery 
events Genotype
SNP 
2 
SNP 
3 
SNP 
4 
SNP 
5 
SNP 
6 
206 1 6  [L52P] / [R390S] C/G G/T G/C T/C A 
110 1 4  [A106D] / [A106D] C G G T A 
161 <1 3  [1236-1237insC] / [1436-1448del13] C G G T A 
164 <1 3  [A106D] / [1775-1801dup27] C G G T A 
113 1 3  [1436-1448del13] / - C G G T A 
2 1 2  [W57X] / [1775-1801dup27] C G G T A 
67 1 2  [G61E] / [1436-1448del13] C G G T A 
71 1 2 [1236-1237insC] / [1775-1801dup27] C G G T A 
153 <1 2  [G61E] / [1436-1448del13] C G G T A 
12 2 4  [G61E] / [1236-1237insC] C G G T A 
25 3 8  [1775-1801dup27] / [1775-1801dup27] C G G T A 
42 3 7  [G61E] / - * C G G/C T/C A/G 
63 5 3  [R355X] / [E387K] C/G G/T G/C T/C A 
1 5 2  [W57X] / [1775-1801dup27] C G G T A 
16 6 2  [L26R] / [R368H] C G G T A 
203 8 3  [A443G] / - C/G G/T G T A 
31 <1 1  [G61E] / [P52L] C G G T A 
54 1 1  [M1T] / [R368H] C G G T A 
62 12 0  [R355X] / [E387K] C/G G/T G/C T/C A 
89 <1 0  [G61E] / [1236-1237insC] C G G T A 
122 17 y 0  [G61E] / [G61E] C G G T A 
179 <1 0  [A237E] / [1581-1582ins10] C G C T A 
91 4 y 0  [1236-1237insC] / - C G G/C T/C A 
114 29 y 0  [1436-1448del13] / - C G G T A 
132 3 y 0  [G61E] / - C G G/C T/C A/G 
Table I. Phenotype–Genotype Correlation in Italian CG patients with CYP1B1 mutations. 
SNP 1–5 are: 1. 3947 C>G (R48G); 2. 4160 G>T (A119S); 3. 8131C>G (L432V); 4. 8184C>T 
(D449D); 5. 8195A>G (N435S).  
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2.2 Mutation screening  
DNA was extracted from peripheral blood of patients and family members. The entire 
transcript region of the CYP1B1 gene, organized in three exons of which only II and III are 
translated, was screened for mutations using four sets of  primers:  
set1 - cyp1b1Ex1F 5’-GCT TTG ACT CTG GAG TGG G-3’and cyp1b1Ex1R 5’-TCC ATC TGA 
AGA GGT CGC C-3’ (424 bp); set2 - cyp1b1Ex2aF 5’-TGA GTG TCA CGC CTT CTC C-3’ 
and cyp1b1Ex2aR 5’-CTC AGC ACG TGG CCC TC-3’ (548 bp); set3 - cyp1b1Ex2bF 5’-ATG 
CGC AAC TTC TTC ACG-3’ and cyp1b1Ex2bR 5’-AGA GGA GAA AAG ACC TGG C-3’ 
(631 bp); set4 - cyp1b1Ex3F 5’-TGC TCA CTT GCT TTT CTC TC-3’ and cyp1b1Ex3R 5’-ATT 
TTA CTC CTC ATC TCC GAA-3’ (691 bp). Polymerase chain reaction (PCR) amplification 
was performed in a 50-µL volume consisting of 50 to 100 ng genomic DNA, 10 mM Tris-HCl 
(pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 0.8 M of each primer and 1 U Taq 
polymerase (AmpliTaq Polimerase - Perkin Elmer) with 10% dimethyl sulfoxide (DMSO) 
only for set 2 and set 3. PCR amplification procedures were performed under the following 
conditions: for set 1 and set 4,  2 cycles consisting of 60 seconds at 94°C, 30 seconds at 52°C 
and 90 seconds at 72°C followed by 35 cycles each consisting of 30 seconds at 94°C, 30 
seconds at 54°C and 90 seconds at 72°C, followed by a final extension of 7 minutes at 72°C; 
for set 2 and set 3, 12 cycles consisting of 60 seconds at 94°C, 120 seconds at 64°C with a 
decrement of 1° C every cycle and 180 seconds at 72°C followed by 25 cycles each consisting 
of 60 seconds at 94°C, 120 seconds at 52°C and 5 minutes at 72°C, followed by a final 
extension of  7 minutes at 72°C. 
Patients with none or only one mutation in the CYP1B1 gene were screened for mutations in 
the transcript region of the MYOC/TIGR gene using three sets of  primers: 
Set 1 - myocEx1F 5’-GGC TGG CTC CCC AGT ATA TA - 3’and myoc1Ex1R 5’-CTG CTG 
AAC TCA GAG TCC CC- 3’ ( 760 bp); set 2 - myocEx2F 5’-AAC ATA GTC AAT CCT TGG 
GCC- 3’ and myocEx2R 5’- TAA AGA CCA TGT GGG CAC AA- 3’ ( 230 bp); set 3 - 
myocEx3F 5’-TTA TGG ATT AAG TGG TGC TTC G- 3’ and myocEx3R 5’- AGC ATC TCC 
TTC TGC CAT TG- 3’ (870 bp). PCR amplification was performed in a 25-µL volume 
consisting of 50 to 100 ng genomic DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM 
MgCl2, 0.2 mM dNTPs, 0.8 M of each primer and 1 U Taq polymerase (AmpliTaq Polimerase 
- Perkin Elmer). PCR amplification procedures were performed as follows: 35 cycles 
consisting of 60 seconds at 94°C, 60 seconds at 55°C and 120 seconds at 72°C followed by a 
final extension of 7 minutes at 72°C. 
PCR products were sequenced on an automated DNA sequencer (ABI-310; PE Applied 
Biosystems).  
Every nucleotide change is indicated using the sequence of the cDNA published with the 
accession number NM_000104.2 for the CYP1B1 and NM_000261 for the MYOC/TIGR 
transcript. The position of mutations were described as in Recommendations for a 
Nomenclature System for Human Gene Mutations (Antonarakis et al., 1998). 
2.3 Comparative sequencing alignment 
The cytochrome P4501B1 and MYOC/TIGR sequences were obtained from GenBank  
provided by the National Center for Biotechnology Information, Bethesda, MD, USA 
(http://ww.ncbi.nlm.nih.gov/Genbank).  
Computer-assisted sequence alignment was performed with the pattern-induced 
multisequence alignment program (PIMA; provided by Baylor College of Medicine Search 
Launcher and available at: http://searchlauncher.bcm.tmc.edu). 
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3. Results 
3.1 CYP1B1 gene sequence analysis 
Twenty-five patients (34,7%) were carriers of mutations in the coding region of CYP1B1 
gene: 17 were compound heterozygotes, 2 were homozygotes, 6 carried only one mutation 
in a single allele (Table  II). 
The analysis was also performed on relatives of mutated subjects in order to verify the allele 
segregation and to complete the family study. 
 
Exon  Effect Patients 
N (%) of 
affected 
chromosomes 
(n=44) 
     
2 T374C M1T 54 1 (2.3%) 
2 T449G L26R ^ 16 1 (2.3%) 
2 C527T P52L*^ 31, 206 2 (4.5%) 
2 G543A W57X 1, 2 2 (4.5%) 
2 G554A G61E 
12, 31, 67, 89, 122, 153, 
42, 131 
9 (20.5%) 
2 C689A A106D^ 110, 164 3 (6.8%) 
2 C1082A A237E^ 179 1 (2.3%) 
2 1236-1237insC 
Frameshit beginning 
from aa 288 
12, 71, 89, 91, 161 5 (11.4%) 
3 C1435T R355X 62, 63 2 (4.5%) 
3 1436-1448del13 
Frameshit beginning 
from aa 355 
67, 113, 114, 153, 161  5 (11.4%) 
3 G1475A R368H 16, 31 2 (4.5%) 
3 G1531A E387K 62, 63 2 (4.5%) 
3 C1540A R390S 206 1 (2.3%) 
3 1581-1582ins10 
Frameshit beginning 
from aa 404 
179 1 (2.3%) 
3 T1692G F440L*^ 31, 206  
3 C1700G A443G 203 1 (2.3%) 
3 1775-1801dup27
Frameshit beginning 
from aa 468 
1, 2, 25, 71, 164 6 (13.6%) 
* present on the same chromosome inherited from the unaffected father, in patients 31 and 206 who are 
also compound heterozygotes for other published pathological mutations (G61E and R390S 
respectively). 
^ new variations 
Table II. Frequencies of CYP1B1 mutations in the Italian population 
Out of the seventeen different CYP1B1 variations identified, twelve had been previously 
characterized as pathogenetic: six aminoacid substitutions (M1T, G61E, R368H, E387K, 
R390S and A443G), two stop codons (W57X, R355X), two insertions (1236-1237insC and 
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1581-1582ins TCATGCCACC), one deletion (1436-1448delGAGTGCAGGCAGA) and one 
duplication (1775-1801dupGGCGGTGCATTGGCGAAGAACTTTCTA). Five variations 
(L26R, P52L, A106D, A237E, F440L) are described here for the first time (Table II). 
The new variants show the following characteristics: L26R, which affects the second nucleotide 
of codon 26, substitutes leucine, an aliphatic and hydrophobic residue with a polar and 
hydrophilic arginine. The variation L26R is present in patient 16 with the known mutation 
R368H. A237E presents a substitution of an alanine, weakly hydrophobic with small nonpolar 
side chains, with glutamic acid that carries a hydrophilic acidic group with strong negative 
charge and was found in patient 179 associated with the insertion 1581-1582ins10.  
A106D was observed on three CG chromosomes (patient 110 is homozygous and patient 164 
is compound heterozygote with the known mutation 1775-1801dup27). This change causes a 
missense substitution of alanine (weakly hydrophobic with small nonpolar side chains) with 
asparagine (with polar, uncharged side chains).  
P52L changes proline, often present in the protein turning point and with small nonpolar 
side chains, to leucine (aliphatic and hydrophobic). F440L changes phenylalanine, a 
hydrophobic aminoacid usually orientated towards the interior of the folded protein, to 
leucine with the same characteristics as phenylalanine.  
The variations P52L and F440L are present in cis in patients 31 and 206, who are also 
compound heterozygotes for other published pathological mutations (G61E and R390S 
respectively); these patients are from the same Italian region.  
All new identified aminoacidic changes alter residues that are evolutionarily conserved in 
Eukariota and in the cytochrome P450 family (Figs. # 1 and 2). 
The most frequent mutations in our CG patients are G61E, 1775-1801dup27, 1436-1448del13 
and 1236-1237insC; they occur respectively in 20.5%, 13.6%, 11.4% and 11,4% of mutated 
chromosomes (Table II).  
Two nucleotide variants were found in the untranslated exon 1: one of these (cDNA 198 C/T) 
was characterized as a single nucleotide polymorphism (NCBI SNPs databank rs 9341244) 
while the second one (C>A at 226 of cDNA) was identified for the first time in patient 91.  
In these 72 Italian CG subjects we also identified 6 Single Nucleotide Polymorphisms 
previously described and 2 new synonymous changes (G/A 359E and C/T 363V) whose 
frequencies are 1/144 and 3/144 respectively. 
3.2 CYP1B1 SNP haplotypes 
We analyzed the following known CYP1B1 polymorphisms (Akarsu et al., 2002, Sutter et al., 
2005, Fan et al., 2004) in our patients: g.3947C>G, g.4160G>T, g.8131C>G, g.8184C>T, 
g.8195A>G. (Table II). The most frequent haplotype in individuals with CYP1B1 mutations 
is 5'-C-G-G-T-A-3', as already described in other populations (Belmouden et al.,2002, Kaur et 
al., 2005, Bejjani et al., 1998, Stoilov et al., 2001). This haplotype is present in 41 of the 44 
mutated alleles (93%), and in only 20 of the remaining 100 wild type alleles (20%); the 
difference is  statistically significant (Q2= 22.23, p < 0.0001, CI95% 0.555-0.905). 
Considering the seventeen mutations we found, fifteen are linked to the 5'-C-G-G-T-A-3'  
haplotype and two (E387K and R390S) are associated with two other different haplotypes. 
3.3 MYOC/TIGR gene analysis 
The report in published papers of patients with mutations in either CYP1B1 and MYOC 
genes prompted us to look for MYOC/TIGR variations in the six patients having only one 
mutation in CYP1B1.  
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Fig. 1. Aminoacidic Sequence Alignment of CYP1B1 and homolous genes in Eukariota. Lane 
1:CYP1B1 H.sapiens , lane 2 LOC483038 C.familiaris, lane 3: Cyp1b1 M.musculus, lane 4: 
LOC421466 G.gallus, lane 5: spo D.melanogaster. 
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Fig. 2. Aminoacidic Sequence Alignment of CYP1B1 (second lane) and other P450 family  
members (CYP2b4, CYP17A1,  CYP2C22, CYP2C3,  CYP2C7, CYP2C1, CYP2C23, CYP2D14, 
CYP2D4) . 
The analysis of the complete MYOC gene sequence identified, in three patients, two 
transitions (G>A at 249 and C>T at 1362 cDNA positions) causing the two aminoacidic 
variations R76K and A447V. Lysine in position 76 is similar to Arginine; Valine in position 
447, an aminoacid with a large aliphatic hydrophobic side chain, usually located inside the 
protein, substitutes Alanine that has only small steric limits and can be located in the 
hydrophilic areas either outside or in the hydrophobic areas inside the protein.  
In patient 42 the A447V is present with the G61E common CYP1B1 mutation; two mutations 
are distinctly inherited from the two parents. Patient 132, with a single maternally 
transmitted CYP1B1 G61E mutation, inherited R76K from the father while patient 203 
received both the R76K and the CYP1B1 A443G from the unaffected father, who is 
homozygotes for R76K. 
To confirm the polymorphic role of R76K, already suggested in literature (Colomb et al., 
2003, Edward et al., 2004), we analyzed 100 chromosomes in a random Italian population, 
obtaining a frequency of 0,125 and 0,875 for the A and G alleles respectively. 
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4. Discussion 
Molecular analysis of the CYP1B1 gene performed on 72 Italian patients with found eighteen 
different variations in 25 (34.7%) individuals. Four of these variations (L26R, P52L, A106D, 
A237E) are reported here for the first time and produced a non synonymous aminoacidic 
change. Their pathological role in CG development could be an explanation for the significant 
changes in the protein caused by the aminoacidic substitutions in Eukariota and cytochrome 
P450 family conserved regions. The new changes are in a compound heterozygous state with 
already described pathological mutations and are distributed in exon # 2 and 3.  
The conservative aminoacid change F440L always found in cis with the P52L in 4 subjects, 
both in patients (with another CYP1B1 mutation) and in healthy carriers, could be classified 
as a rare polymorphism linked to the pathological P52L. 
One of the two nucleotide variants we identified in the untranslated exon 1 had not been 
previously reported. In patient 91 a C to A at position 226cDNA was found combined with 
the pathological mutation 1236-1237insC. The presence in cis with the CG mutation also in 
the unaffected mother suggests that this ex1UTR variation does not play a pathological role 
in CG development.  
We identified two new synonymous changes (G >A at the Glutamic Acid in position 359 
and C>T at the Valine in position 363) in 2 different patients. These variations do not 
introduce aminoacidic changes and were not found in 100 analyzed chromosomes, so we 
can consider them as rare polymorphisms. 
Clinical evaluation of patients cannot show a particular phenotype-genotype correlation 
even if mutations that produce truncated proteins seem more frequent in patients with a 
disease onset before the first year of life and more then two surgical procedures.  
As also described in Indian and Saudi Arabian populations, we identified the M1T and 
W57X CYP1B1 mutations that have been previously associated only with Peters’ anomaly, 
in three of our CG patients. These results support the concept that distinct CYP1B1 
mutations are not responsible for the two different diseases and that a specific phenotype 
could result from interactions between CYP1B1 and other modifier genes. 
The previously described CYP1B1 intragenic polymorphisms (R48G, A119S, L432V, D449D 
and N453S) were analyzed and the most frequent haplotype (93%) among affected 
individuals with CYP1B1 mutations appears to be 5'-C-G-G-T-A-3', which has been 
associated with fifteen different mutations. This particular haplotype was also observed in 
94.7% of the Saudi Arabian and in the majority of the Brazilian CG chromosomes. 
Interestingly, in our 47 CG patients without mutations in CYP1B1, the frequency of the 5'-C-
G-G-T-A-3' haplotype is the same as the general Italian population (23% vs 20%). The 
association of this specific uncommon haplotype with the majority of CYP1B1 mutations in 
geographically and ethnically distinct populations could confirm the hypothesis that this 
DNA sequence predisposes the gene to mutational events as already suggested. 
The presence in other populations of patients with mutations in both CYP1B1 and MYOC 
genes prompted us to analyze the six patients that had only one mutation in CYP1B1 for the 
presence of MYOC/TIGR variations. The R76K was found in compound heterozygosis in 
patient 132 and 203 with the G61E and A443G CYP1B1 mutations respectively. The presence 
of MYOC R76K aminoacidic change in both alleles of patient 203’s unaffected father, who 
also had a CYP1B1 mutation, defines the non pathological role of this variation, confirmed 
as a polymorphism in an Italian population frequency of  0.125 and 0.875 for the A and G 
alleles respectively.  
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In patient 42 we found, in double heterozygous status with the CYP1B1 G61E, the new 
MYOC variation A447V. This substitution affects a conserved aminoacidic position and 
introduces a residue with peculiar characteristics that can alter the protein functions. The 
two mutations are distinctly inherited from the unaffected heterozygous parents and the 
A447V was not found in 100 control chromosomes. This is the first report of CYP1B1 and 
MYOC mutations in Italian patients with congenital glaucoma.  
The molecular characterisation of both CYP1B1 and MYOC/TIGR genes in affected subjects 
allowed us to better clarify the genetic basis of the CG disease. Our results confirm the major 
role of CYP1B1 in congenital glaucoma and also support an autosomic recessive role of 
MYOC/TIGR gene in a digenic inheritance model. The presence of only one CYP1B1 
mutation in 5 patients confirms that other genes could interact with the function of the 
CYP1B1 codified protein in CG onset with different digenic inheritances. We did not look 
for and we did not find any genotype and phenotype correlations in our patients (Hollander 
et al., 2006). A study of Iranian patients did not find any myocilin mutations as cause of 
congenital glaucoma (Elahi et al., 2010). 
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